LGLeah M. Grant

Leah M. Grant

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Leah M. Grant has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cervical, Mediastinal, and Pericardial Disseminated Coccidioidomycosis: The Importance of Source Control

    by Leah Grant, Seth Assar, Farhan Taghizadeh, Joann Hutto, Neil M. Ampel

    A 47‐year‐old healthy man developed disseminated coccidioidomycosis involving his mediastinal and cervical lymph nodes that was complicated by pericardial involvement despite continued fluconazole for primary pulmonary infection. Although he subsequently received an aggressive antifungal regimen with voriconazole and liposomal amphotericin B, he did not clinically improve until he underwent major debridement and drainage, highlighting the need for source‐control procedures in some cases of severe disseminated coccidioidomycosis.

  • Open Access

    Positive impact of a diagnostic stewardship intervention on syndromic panel ordering practices and inappropriate C. difficile treatment

    by Dan Ilges, Erin H. Graf, Leah Grant, Ashley Long, Eric Siebeneck, Maria Teresa Seville, Thomas Grys, Lisa J. Speiser

    Objective: Multiplex polymerase chain reaction (PCR) panels for stool testing may be used to diagnose Clostridioides difficile, which can circumvent more appropriate targeted C. difficile testing, resulting in treatment of incidentally detected colonization. We sought to reduce C. difficile diagnosis via a gastrointestinal pathogen panel (GIPP).Design: Quasi-experimental, pre/post, retrospective cohort study from January 1, 2022, to January 31, 2024.Setting: Mayo Clinic Arizona—a single academic medical center and associated clinics.Patients: Adult patients receiving C. difficile testing and/or treatment.Methods: Preferred C. difficile testing consisted of glutamate dehydrogenase and toxin antigen immunoassay, followed by toxin gene testing for discrepant results. The GIPP contained 22 targets during the baseline period with C. difficile removed during the postintervention period. Surveys were provided to provider and nursing groups, separately, to identify C. difficile ordering practices and knowledge gaps.Results: At baseline, from January 1, 2022, to January 31, 2023, 2,772 GIPPs were completed for 2,307 unique patients (∼7 per day), primarily for outpatients (1,805 of 2,772, 65%). The most common positive target was C. difficile (517 of 1,018, 51%), which resulted in treatment for C. difficile infection in 94.9% (337 of 355) of cases. Following GIPP C. difficile target removal, GIPP orders decreased from 3.23 to 2.7 per 1,000 patient visits (P < .001). Prescribing of C. difficile treatments decreased in the postintervention period in inpatient and outpatient settings. There were no cases of delayed C. difficile diagnosis during the postintervention period.Conclusions: Removing C. difficile from the GIPP resulted in effective diagnostic and antimicrobial stewardship without resulting in delayed diagnoses.


  • Brain abscess following solid organ transplantation: A 21‐year retrospective study

    by Leah M. Grant, Pool J. Tobar Vega, Reena N. Yaman, Marlene E. Girardo, Elena Beam, Raymund R. Razonable, Christopher F. Saling, Holenarasipur R. Vikram

    Background: Development of brain abscess following solid organ transplantation is associated with significant morbidity and mortality. We undertook a descriptive study to evaluate the etiology, clinical manifestations, diagnosis, management, and outcomes of brain abscess in solid organ transplant (SOT) recipients at three major transplant centers in the United States.Methods: This is a retrospective study of adults with brain abscess following SOT between January 2000 and June 2021 at Mayo Clinic sites in Arizona, Minnesota, and Florida.Results: A total of 39 patients were diagnosed with a brain abscess following SOT. The most common pathogens were Nocardia sp. (24 cases, 61.5% [Nocardia farcinica, 37.5%]), followed by fungi (12 cases, 30.7% [Aspergillus sp., 83.3%]). The majority were kidney transplant recipients (59%). Median time to brain abscess diagnosis was 1.3 years (range, 29 days–12 years) after SOT; 10 of 12 patients (83%) with fungal brain abscess were diagnosed within 1 year after SOT. Twelve patients underwent brain biopsy for diagnosis (25% Nocardia vs. 50% fungal), eight (20.5%) underwent surgical resection of the abscess, and 31 (79.5%) received antimicrobial therapy alone. Median time to brain abscess resolution was 166 days for Nocardia and 356 days for fungal pathogens. Eleven of 39 patients (28.2%) died as a result of their brain abscess, including four of 24 patients (16%) with Nocardia and six of 10 patients (60%) with Aspergillus brain abscess. All‐cause mortality was 43.6%.Conclusion: Brain abscess remains an uncommon infectious complication following SOT. Nocardia and fungi accounted for 92% of pathogens in our cohort. Fungal brain abscess portends a poor prognosis. image


  • Rhodococcus erythropolis septic arthritis

    by Leah M Grant, Maria T Seville, Erin H Graf, Holenarasipur R Vikram

    A woman in her 50s presented with a 4-day history of left knee pain, erythema, swelling as well as malaise and rigours 1 month after undergoing a left knee meniscectomy. She was diagnosed with left native knee septic arthritis and underwent arthroscopic irrigation and debridement of the knee; cultures from synovial tissue grew Rhodococcus erythropolis. Rhodococcus spp are soil-dwelling and livestock-dwelling bacteria which occasionally cause disease in immunocompromised hosts. Infection in immunocompetent hosts is rare, and septic arthritis secondary to Rhodococcus erythropolis has not been reported previously.


  • Open Access

    Facial skin lesions and diarrhea in a kidney transplant recipient

    by Leah M. Grant, Amy Kole, Dora M. Lam-Himlin, Holenarasipur R. Vikram

  • Open Access

    Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp

    by Leah M. Grant, Robert Orenstein

    Recurrent vulvovaginal candidiasis is a common disorder which causes significant morbidity among women worldwide, and treatment options are limited. Ibrexafungerp is a novel antifungal agent which was approved in 2021 for treatment of vulvovaginal candidiasis. We present a case of recurrent vulvovaginal candidiasis successfully treated with ibrexafungerp.


  • One man, three tick-borne illnesses

    by Leah Grant, Imran Mohamedy, Laura Loertscher

    A 70-year-old man presented to the emergency department with fevers, ankle edema and nausea following a presumed insect bite on his ankle 1 month prior. On examination, he was febrile and had left leg pain with passive range of motion. Laboratory studies revealed anemia, thrombocytopenia, acute kidney injury and elevated aminotransaminases. Due to his recent travel to the Northeastern United States, he was suspected of having a possible tick-borne illness. Serologies were positive for Borrelia burgdorferi, Anaplasma phagocytophilum and Babesia microti, and the patient was diagnosed with Lyme disease, babesiosis and anaplasmosis. He was treated with doxycyline, atovaquone and azithromycin, leading to resolution of symptoms. While co-infection with Lyme disease is common, infection with three tickborne illnesses at one time is relatively rare.